Flupentixol/melitracen

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Flupentixol/melitracen
Combination of
Flupentixol Typical antipsychotic
Melitracen Tricyclic antidepressant
Clinical data
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
  (verify)

Flupentixol/melitracen (trade name Deanxit, Placida, Franxit, Anxidreg, Danxipress) is a combination of two psychoactive agents (a typical antipsychotic drug of the thioxanthene class) and tricyclic antidepressant (TCA)) which has antidepressant properties. It is designed for short term usage only. It is produced by Lundbeck.[1]

Flupentixol/melitracen were banned in India by the country's Ministry of Health and Family Welfare on July 11, 2014,[2] and Lundbeck plans to take legal action to have the ban lifted.[3]. As of 2014, Deanxit is banned in the United States, Canada, India, Japan, Australia, United Kingdom and Denmark due to its lack of clinical trials and untested compounds in the drugs, notes The Economic Times[4] and other sources[5]. Another reason for the ban is due to flupentixol's serious neurological side effects, according to PharmaBiz.com[6].

Other Brand names[edit]

Brand names include:

  • Pentoxol.m (scotmann pharmaceuticals pakistan)
  • Sensit (Eskayef Bangladesh Ltd.)
  • Renxit (Renata Ltd.)
  • Melixol (Square Pharmaceuticals Ltd.)
  • Melanxit (Organic Health Care Ltd.)
  • Benzit (Bio-Pharma Ltd.)
  • Leanxit (ACME Laboratories Ltd.)
  • Danxipress (Vickmans Lab Ltd.)

See also[edit]

References[edit]